Salim Ben Yahia, Rim Kahloun, Salma Gargouri, Rim Ghrissi, Riadh Messaoud, Moncef Khairallah (Monastir, Tunisia)

Advantages:

To manage choroidal neovascularization (CNV) secondary to angioid streaks with intravitreal injection of bevacizumab.

Methods:

Eight eyes of 8 patients with CNV secondary to angioid streaks were treated with intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. Main outcome measures included changes in best-corrected visual acuity, optical coherence tomography features, and leakage on fluorescein angiography. Mean follow-up was 10 months.

Effectiveness / Safety:

Visual acuity improved from 20/200 at presentation to 20/63 at the last follow-up visit.  Complete closure of CNV, without recurrences during the follow-up period, occurred in 5 eyes (62.5%). Recurrences of CNV were noted in 3 eyes (37.5%), requiring a second injection for one patient, 2 injections for the second patient, and 3 injections for the third patient. No ocular or systemic side effects were observed.

Take home message:

Intravitreal bevacizumab therapy seems to be a safe and effective treatment for choroidal neovascularization secondary to angioid streaks. As observed with other therapeutic options, recurrences were not rare.